Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ENTX 
Entera Bio Ltd (ENTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ENTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10
1 Year Target Price $10
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 10.07% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 88.59M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 1 | Beta 1.52 | 52 Weeks Range 1.50 - 2.79 | Updated Date 08/28/2025 |
52 Weeks Range 1.50 - 2.79 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.26 |
Earnings Date
Report Date 2025-08-11 | When - | Estimate -0.11 | Actual -0.06 |
Profitability
Profit Margin - | Operating Margin (TTM) -6378.92% |
Management Effectiveness
Return on Assets (TTM) -44.56% | Return on Equity (TTM) -82.22% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 78845226 | Price to Sales(TTM) 533.66 |
Enterprise Value 78845226 | Price to Sales(TTM) 533.66 | ||
Enterprise Value to Revenue 474.97 | Enterprise Value to EBITDA -1.52 | Shares Outstanding 45663400 | Shares Floating 28765647 |
Shares Outstanding 45663400 | Shares Floating 28765647 | ||
Percent Insiders 24.31 | Percent Institutions 22.36 |
Upturn AI SWOT
Entera Bio Ltd
Company Overview
History and Background
Entera Bio Ltd. (ENTX) is a clinical-stage biopharmaceutical company focused on developing orally delivered large molecule therapeutics for unmet medical needs. Founded in 2010 in Israel, it aims to transform peptide and protein delivery through its proprietary technology. Significant milestones include progressing its lead candidate, EB613, through clinical trials and strategic partnerships.
Core Business Areas
- Oral Delivery Technology: Developing oral formulations of large molecules, specifically peptides and proteins, which are traditionally administered via injection.
- EB613 (Osteoporosis Treatment): Developing EB613 as an oral treatment for osteoporosis, targeting increased bone mineral density and fracture prevention.
Leadership and Structure
Entera Bio Ltd. is led by a management team with expertise in pharmaceutical development and business strategy. The company operates with a structure typical of a clinical-stage biotech, focusing on research, development, and clinical trials.
Top Products and Market Share
Key Offerings
- EB613: EB613 is Entera Bio's lead product candidate, an oral formulation of synthetic parathyroid hormone (PTH) for the treatment of osteoporosis. Currently in clinical development, no revenue generated yet. Competitors include injectable PTH therapies such as Eli Lilly's Forteo and Amgen's Prolia.
Market Dynamics
Industry Overview
The pharmaceutical industry is witnessing a growing interest in oral delivery of biologics, driven by patient preference and improved convenience. The osteoporosis market is substantial, with a significant unmet need for effective and convenient oral treatments.
Positioning
Entera Bio is positioning itself as a leader in oral delivery of large molecules, specifically targeting the osteoporosis market with EB613. Its competitive advantage lies in its proprietary oral delivery technology.
Total Addressable Market (TAM)
The global osteoporosis market is projected to reach $15.5 billion by 2027. Entera Bio is positioned to capture a share of this market with a successful oral therapy.
Upturn SWOT Analysis
Strengths
- Proprietary oral delivery technology
- Lead product candidate targeting a large market (osteoporosis)
- Experienced management team
Weaknesses
- Clinical-stage company with no revenue-generating products
- High dependence on successful clinical trial outcomes
- Limited financial resources compared to larger pharmaceutical companies
Opportunities
- Positive clinical trial results for EB613
- Partnerships with larger pharmaceutical companies
- Expansion into other therapeutic areas with its oral delivery technology
Threats
- Failure of EB613 in clinical trials
- Competition from existing osteoporosis treatments
- Regulatory hurdles and delays
Competitors and Market Share
Key Competitors
- LLY
- AMGN
- Radius Health (RDUS) (NOTE: RDUS Acquired by Jeil Pharmaceutical)
Competitive Landscape
Entera Bio's main competitive advantage is the oral route of administration. Current competitors rely on injectable osteoporosis treatments. A successful oral formulation would offer significant convenience benefits to patients.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by advancement of EB613 through clinical trials, rather than revenue generation.
Future Projections: Future growth depends on positive clinical trial results for EB613 and potential partnerships. Analyst estimates depend on the success of EB613. There is no guarantee that the company will ever make a profit.
Recent Initiatives: Recent initiatives include ongoing clinical trials for EB613 and exploration of other applications for its oral delivery technology.
Summary
Entera Bio is a clinical-stage biopharmaceutical company with a promising oral delivery technology targeting osteoporosis. Its success is heavily reliant on positive clinical trial outcomes for EB613 and securing partnerships. While the potential market is substantial, the company faces significant clinical and financial risks. With the clinical-stage of the company, the financial health is weak, with most of its worth placed on it's intellectual property and ability to progress through clinical trials. The company needs to ensure it has adequate cash reserves for all clinical trials.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Entera Bio Ltd. investor relations website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share estimates are approximate and subject to change. Future projections are based on assumptions and may not materialize.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Entera Bio Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2018-06-28 | CEO & Director Ms. Miranda J. Toledano M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 19 | Website https://www.enterabio.com |
Full time employees 19 | Website https://www.enterabio.com | ||
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial for the treatment of post-menopausal women with low bone mineral density and high-risk osteoporosis; and has completed Phase 1 clinical trial to treat stress fractures. In addition, the company is developing EB612, a tablet peptide replacement therapy for hypoparathyroidism. Further, it develops oral oxyntomodulin (OXM), a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity and metabolic disorders; and GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions, such as short bowel syndrome. The company has research collaboration agreement with OPKO Biologics, Inc. Entera Bio Ltd. was incorporated in 2009 and is headquartered in Jerusalem, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.